0001209191-23-050192.txt : 20230920
0001209191-23-050192.hdr.sgml : 20230920
20230920175051
ACCESSION NUMBER: 0001209191-23-050192
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230919
FILED AS OF DATE: 20230920
DATE AS OF CHANGE: 20230920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FINCK BARBARA K
CENTRAL INDEX KEY: 0001242116
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38052
FILM NUMBER: 231267399
MAIL ADDRESS:
STREET 1: C/O PROTINE DESIGN LAB
STREET 2: 3858 JACKSON ST
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Forte Biosciences, Inc.
CENTRAL INDEX KEY: 0001419041
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261243872
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (310) 618-6994
MAIL ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
FORMER COMPANY:
FORMER CONFORMED NAME: Tocagen Inc
DATE OF NAME CHANGE: 20071120
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-19
0
0001419041
Forte Biosciences, Inc.
FBRX
0001242116
FINCK BARBARA K
C/O FORTE BIOSCIENCES, INC.
3060 PEGASUS PARK DR., BUILDING 6
DALLAS
TX
75247
1
0
0
0
0
Stock Option (right to buy)
0.80
2023-09-19
4
A
0
25000
0.00
A
2033-09-19
Common Stock
25000
25000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023.
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
2023-09-20